Physicians' Academy for Cardiovascular Education

Hypertension

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)

Starting with quarter-dose quadruple combination pill effectively lowers BP

News - Sep. 7, 2021

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.

Intensive BP lowering reduces CV events in older patients with hypertension

News - Aug. 30, 2021

ESC 2021 The STEP study showed that intensive BP lowering (SBP target 110 to <130 mmHg) reduced the risk of CV events in older patients with hypertension, compared to standard treatment (SBP target 130 to <150 mmHg).

Replacing salt with a salt substitute reduces risk of stroke

News - Aug. 29, 2021
The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.

ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.

ARNI potential treatment for apparent resistant hypertension in HFpEF

Literature - Aug. 23, 2021 - Jackson AM et al. - Eur Heart J. 2021

This post-hoc analysis of PARAGON-HF suggests that sacubitril/valsartan reduces blood pressure to a greater extent than valsartan in patients with apparent resistant hypertension or apparent MRA-resistant hypertension.

Position paper on renal denervation for the treatment of hypertension

News - Aug. 11, 2021

The European Society of Hypertension has published a position paper on renal denervation (RDN), following the publication of five sham-controlled RCTs which provided evidence that RDN is an effective and safe option for the treatment of hypertension.

Similar effectiveness of ACEi and ARB as hypertension treatment in real-world

Literature - Aug. 9, 2021 - Chen RJ, et al. - Hypertension 2021

There was no difference in CV outcomes with ACEi monotherapy as first-line hypertension treatment compared to ARB monotherapy in a large-scale observational network study.

Hypertension stage 1 at early 40s in women associated with increased ACS risk during midlife

Literature - June 22, 2021 - Kringeland E, et al. - Eur J Prev Cardiol 2021
Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.

Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.

Larger SBP reduction by renal denervation in resistant hypertension patients on combination pill

News - May 17, 2021

ACC 2021 In patients with resistant hypertension despite on a triple medication combination daily pill, renal denervation resulted in a 4.5 mmHg greater decrease after 2 months than a sham control.

Scientifc Statement on adverse pregnancy outcomes and CVD

Literature - Apr. 21, 2021 - Parikh NI et al. - Circulation. 2021

Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.

Nearly linear relationship between sodium intake and BP in individuals with and without hypertension

Literature - Mar. 16, 2021 - Filippini T, et al. - Circulation. 2021

Sodium intake was almost linearly associated with SBP and DBP, without a threshold for low or high sodium exposure. The effect of sodium reduction on BP was more pronounced in individuals with hypertension.

CVD risk associated with lower SBP range in women than in men

Literature - Mar. 5, 2021 - Ji H et al. - Circulation. 2021.

This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.